Floatz logo

Idarubicine

Lymphoma, B-Cell

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
55/ 100
Competitive Position
73/ 100

Competitive context

316 Active assets in the Lymphoma, B-Cell cohort.

Asset / SponsorPhaseRating
VINDESINE
Children's Cancer Group, China
Phase 4BBB
Odronextamab
University of Birmingham
Phase 3BBB
cc-5013
Shanghai Junshi Bioscience Co., Ltd.
Phase 4BBB
METHOTREXATE
Children's Cancer Group, China
Phase 4BBB
Cytosin-Arabinosid
Children's Cancer Group, China
Phase 4BBB

View all 50 →

Same molecule, other indications

Idarubicine is also rated in:

acute promyelocytic leukemiaDormant
A
Indicative ·
81 / 100
View asset →
Acute Promyelocytic LeukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →